For decades, corporate merger and acquisition deals have been plagued by meritless claims asserting, typically, that the companies and their officers and directors have provided insufficient disclosures.
For decades, corporate merger and acquisition deals have been plagued by meritless claims asserting, typically, that the companies and their officers and directors have provided.
In a series of inter partes review ("IPR") proceedings between JSR Corporation and Cytiva Bioprocess R&D AB,[1] the Patent Trial and Appeal Board ("PTAB" or "Board"), determined that some challenged claims.
There are some cases where the Federal Circuit makes its decision based on the eternal verities of patent law (insofar as there are any eternal verities in patent law). One such.